Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414426 · ClinicalTrials.gov registry record · Phase 2
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01414426: Completed Phase 2 study, sponsored by University of Chicago.
NCT01414426 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01414426, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions
Primary Outcome
A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 2 |
What the finished NCT01414426 record still lists
NCT01414426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01414426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01414426 about?
NCT01414426 is a clinical study titled "Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions". This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premal...
What is the current status of trial NCT01414426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT01414426?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), vandetanib (DRUG).
Who is sponsoring clinical trial NCT01414426?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01414426's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia